SecBot SecBot

KURA drug pipeline

Kura Oncology, Inc. · 2 rated drugs
$7.09
−8.8% 1-day · Nov 16
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
±5.3%
1-day, median of 2 events
IV rank
No data
No current options data
Rated drugs
2
1 mixed · 1 neutral
Phase 3 trials
0
0 with results posted

Drugs

soonest catalyst first
● neutral
Impact
PhasePhase 1
Time to marketLikely 4-6+ years if successful; still in Phase 1 with registrational Phase 3 planned for 2028 at the earliest

darlifarnib Updated Jul 14

What to watch

Investors should watch the KCRS 2026 oral presentation on July 24 and the virtual investor call on July 27 for updated long-term Phase 1a durability data in ccRCC. The program is too early for binary positioning, the real value inflection points (Phase 1b randomization data, Phase 3 start in 2028, and the daraxonrasib combo entering the clinic in early 2027) are 12+ months away. KURA is a multi-asset company with an approved product, so darlifarnib is one of several value drivers.

Bull case
  • Early Phase 1a data show compelling efficacy: darlifarnib + adagrasib achieved 67% confirmed ORR in pancreatic cancer (historically hard-to-treat), 50% in NSCLC, and 29% in KRASi-naïve CRC, with tumor shrinkage in 77% of evaluable patients (source: ASCO 2026 presentation via BioSpace press release).
  • The FTI mechanism targets mTORC1-mediated resistance, a well-validated pathway; preclinical data from Cancer Research (May 2026) showed darlifarnib added to RAS inhibitors led to rapid and durable tumor regression in resistant models (source: AACR journal publication).
  • Kura has a strong balance sheet ($667.2M cash as of Q4 2025 + ~$180M in anticipated collaboration payments) funding operations into Q4 2027, providing years of runway to develop darlifarnib without near-term dilution risk (source: Kura Q4 2025 earnings press release, GlobeNewswire).
Bear case
  • Darlifarnib is still only in Phase 1, no randomized controlled data, no Phase 2/3 results. The impressive 67% ORR in pancreatic cancer comes from small patient numbers (single digits) in an early dose-escalation cohort, not a registrational trial (source: ASCO 2026 abstract #3078).
  • The registrational Phase 3 study is not planned until 2028, meaning FDA approval (if any) is 4-6+ years away. The next pivotal catalyst, Phase 1b randomized data, has no announced readout date, leaving a long data gap (source: Kura press releases).
  • Short interest is elevated, the 14-day average short volume ratio was ~48% as of mid-July 2026, with a z-score of +1.84 on July 13 signaling elevated bearish positioning.
◆ mixed
Impact
PhaseApproved
Time to marketAlready approved and commercially available in the U.S. since November 2025.

KOMZIFTI ziftomenib Updated Nov 11

What to watch

KOMZIFTI is already approved and generating growing revenue, so the defining binary event has passed. Watch for ASH 2026 (December 2026) where ziftomenib combination data in newly diagnosed AML will be presented -- strong data could support a major label-expansion opportunity into the frontline setting, while weak data would cap the upside thesis. Also track quarterly sales growth trajectory as the key near-term value driver.

Bull case
  • KOMZIFTI is the first and only FDA-approved once-daily oral menin inhibitor for NPM1-mutated AML, a first-in-class targeted therapy addressing a clear unmet need.
  • Commercial traction is accelerating: Q3 2026 net product revenue of $13.9M grew 53% sequentially, with new patient starts up 30% and total prescriptions rising.
  • Analyst consensus is strongly bullish: 20 buy/strong buy ratings vs 2 hold, with a mean price target of $31.85 (320% upside from the current $7.57).
Bear case
  • The stock trades at $7.57, far below the mean analyst target of $31.85, suggesting the market is heavily discounting the commercial opportunity or sees significant execution risk.
  • Multiple senior executives (CMO, COO, CCO, CLO) sold shares in late September 2026 at ~$10.50, well above the current price, which can signal insider caution about near-term prospects.
  • Several large institutional holders trimmed or exited positions in Q2 2026, including Millennium Management (-55%), Jane Street (-89%), and American Century (-81%), indicating mixed institutional conviction.

Past FDA events & how the stock moved

2 events
DateDrugEvent1 day5 days
Nov 30, 2025KOMZIFTIPDUFA decision−5.8%−1.6%
Nov 13, 2025KOMZIFTIApproval+4.9%+2.8%

Clinical trials

1 Phase 2/3
DrugTrialPhaseStatusEnrolledPrimary completion
TipifarnibCombination Trial of Tipifarnib and Alpelisib in Adult Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)Phase 2Completed45Aug 29, 2025